Primary drug resistance in South Africa: Data from 10 years of surveys

AIDS Research and Human Retroviruses

Volumn 28, Issue 6, 2012, Pages 558-565

  Manasa, Justen ^a   Katzenstein, David ^b   Cassol, Sharon ^c   Newell, Marie Louise ^a   De Oliveira, Tulio ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONFIDENCE INTERVAL; DATA ANALYSIS; DATA MINING; GENE MUTATION; GENE SEQUENCE; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POPULATION RESEARCH; PRIORITY JOURNAL; SEROCONVERSION; SOUTH AFRICA; STATISTICAL SIGNIFICANCE; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; PREVALENCE; SOUTH AFRICA; TIME FACTORS;

EID: 84861863125     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0284     Document Type: Article

References (53)

1. Stevens W, Kaye S, and Corrah T: Antiretroviral therapy in Africa. BMJ 2004;328(7434):280-282.
2. Popp D and Fisher JD: First, do no harm: A call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. AIDS 2002;16(4):676-678.
3. Trotta MP, Ammassari A, Melzi S, et al.: Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S128- 131.
4. Uzochukwu BS, Onwujekwe OE, Onoka AC, Okoli C, Uguru NP, and Chukwuogo OI: Determinants of nonadherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan 2009;24(3):189-196.
5. Mills EJ, Nachega JB, Buchan I, et al.: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA 2006;296(6):679-690.
6. El-Khatib Z, Katzenstein D, Marrone G, et al.: Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS ONE 2011;6(3):e17518.
7. Bennett DE, Bertagnolio S, Sutherland D, and Gilks CF: The World Health Organizatiońs global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13.
8. Mills EJ, Nachega JB, Bangsberg DR, et al.: Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006;3(11):e438.
9. Pillay D: Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004;9(5):695-702.
10. Sagir A, Oette M, Kaiser R, et al.: Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007;60(4):843-848.
11. Weinstock H, Respess R, Heneine W, et al.: Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis 2000;182(1):330-333.
12. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance: Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322(7294):1087-1088.
13. Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288(2):181-188.
14. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347(6):385-394.
15. Weinstock HS, Zaidi I, Heneine W, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1- infected persons in 10 US cities. J Infect Dis 2004;189(12): 2174-2180.
16. Cane P, Chrystie I, Dunn D, et al.: Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ 2005;331(7529):1368.
17. Wensing AM, van De Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192(6):958-966.
18. Hurt CB, McCoy SI, Kuruc J, et al.: Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009;14(5): 673-678.
19. Hamers RL, Siwale M, Wallis CL, et al.: HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010;55(1):95-101.
20. Price MA, Wallis CL, Lakhi S, et al.: Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011;27(1):5-12.
21. Parekh BS, Kennedy MS, Dobbs T, et al.: Quantitative detection of increasing HIV type 1 antibodies after seroconversion: A simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002;18(4):295-307.
22. Myatt M and Bennett DE: A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008;13(Suppl 2):37-48.
23. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, and Gilks FC: Recommendation for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008;13(Suppl 2):12.
24. Barnighausen T, Tanser F, and Newell ML: Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003-2007. AIDS Res Hum Retroviruses 2009;25(4):405-409.
25. Tanser F, Hosegood V, Barnighausen T, et al.: Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol 2008;37(5): 956-962.
26. Tanser F, Barnighausen T, Cooke GS, and Newell ML: Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. Int J Epidemiol 2009;38(4):1008-1016.
27. Houlihan CF, Bland RM, Mutevedzi PC, et al.: Cohort Profile: Hlabisa HIV Treatment and Care Programme. Int J Epidemiol 2011;40(2):318-326.
28. Drummond AJ, Ashton B, Buxton S, et al.: Geneious 5.1. 2010.
29. De Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21(19):3797-3800.
30. Alcantara LC, Cassol S, Libin P, et al.: A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 2009;37(Web Server issue):W634-642.
31. Guindon S and Gascuel O: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood systems biology. Syst Biol 2003;52(5):9.
32. Gifford RJ, Liu TF, Rhee SY, et al.: The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009;25(9): 1197-1198.
33. De Oliveira T, Shafer RW, and Seebregts C: Public database for HIV drug resistance in southern Africa. Nature 2010;464(7289):673.
34. Pillay C, Bredell H, McIntyre J, Gray G, and Morris L: HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses 2002;18(8):605-610.
35. Gordon M, De Oliveira T, Bishop K, et al.: Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: Implications for vaccine and antiretroviral control strategies. J Virol 2003;77(4):2587-2599.
36. Bessong PO, Mphahlele J, Choge IA, et al.: Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses 2006;22(12): 1306-1312.
37. Bessong PO, Larry Obi C, Cilliers T, et al.: Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses 2005;21(1): 103-109.
38. Seoighe C, Ketwaroo F, Pillay V, et al.: A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol 2007;24(4):1025-1031.
39. Jacobs GB, Laten A, van Rensburg EJ, et al.: Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retroviruses 2008;24(7):1009-1012.
40. Pillay V, Ledwaba J, Hunt G, et al.: Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008;13(Suppl 2):101-107.
41. Huang KH, Goedhals D, Fryer H, et al.: Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. Antivir Ther 2009;14(7): 975-984.
42. Matthews PC, Prendergast A, Leslie A, et al.: Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol 2008;82(17):8548-8559.
43. Barnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, and Newell ML: High HIV incidence in a community with high HIV prevalence in rural South Africa: Findings from a prospective population-based study. AIDS 2008;22(1):139-144.
44. Parboosing R, Naidoo A, Gordon M, Taylor M, and Vella V: Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol 2011;83(9):1508-1513.
45. Hamers RL, Wallis CL, Kityo C, et al.: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study. Lancet Infect Dis 2011;11(10):750-759.
46. Little SJ, Koelsch KK, Ignacio C, et al.: Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, 2004, San Francisco, CA.
47. Palmer S, Boltz V, Martinson N, et al.: Persistence of nevirapine- resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006;103(18):7094-7099.
48. Eshleman SH, Mracna M, Guay LA, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15(15):1951-1957.
49. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, and Morris L: Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce motherto- child HIV transmission. AIDS 2006;20(7):995-1002.
50. Little SJ, Frost SD, Wong JK, et al.: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82(11):5510-5518.
51. Barbour JD, Hecht FM, Wrin T, et al.: Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18(12):1683-1689.
52. Ghosn J, Pellegrin I, Goujard C, et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20(2):159-170.
53. Oette M, Kaiser R, Daumer M, et al.: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006;41(5):573-581.